Stevastelin C3

Drug Profile

Stevastelin C3

Alternative Names: NK 374186C3

Latest Information Update: 16 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Kayaku
  • Class Depsipeptides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Immunosuppression; Transplant rejection

Most Recent Events

  • 01 Sep 1998 No-Development-Reported for Immunosuppression in Japan (unspecified route)
  • 01 Sep 1998 No-Development-Reported for Transplant rejection in Japan (unspecified route)
  • 02 Aug 1996 Preclinical development for Immunosuppression in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top